Proteases
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
- B5868 MK3102Summary: Novel long-acting DPP-4 inhibitor
- B5981 DC_AC50Summary: Selective Atox1 and CCS inhibitor
- A8898 HZ-1157Summary: HCV NS3/4A protease inhibitor
- B6133 HexylresorcinolSummary: mushroom tyrosinase inhibitor
- B6189 Sivelestat (ONO-5046)Summary: neutrophil elastase inhibitor
- C3136 P32/98 (hemifumarate)Summary: competitive transition-state substrate analog inhibitor of DPP IV
- C3232 NNGHSummary: cell-permeable, broad-spectrum inhibitor of MMPs
- C3252 Neutrophil Elastase InhibitorSummary: neutrophil elastase inhibitor
- C3265 2-Guanidinoethylmercaptosuccinic AcidSummary: carboxypeptidase E inhibitor
- C3393 PPACKII (trifluoroacetate salt)Summary: glandular and plasma kallikreins inhibitor